The 60P Dengue Program

Dengue infects nearly 400 million people a year across the globe with 2 million to 3 million hospitalizations. The global economic burden exceeds $12 billion annually (Source: UPMC-Health Security). Endemic in most of the equatorial countries, dengue is a growing problem in a number of the world’s largest emerging economies, notably Brazil, India, and Indonesia.The prevalence of dengue has increased dramatically in some developed equatorial economies, e.g. Singapore, which has a historically high level of cases (22,000 in 2013). 
Currently there are no commercially available drugs or vaccines to combat the disease.
  • 60P is developing an alpha glucosidase inhibitor (60P001) and a platelet activating factor receptor antagonist (60P002) for treatment of dengue fever. 
  • A phase IB study has been completed on 60P001 by Duke-NUS Medical School and Singapore General Hospital. 
  • 60P has secured regulatory/ethical approval in Singapore to conduct a phase II study. Upon successful completion, 60P will seek a strategic partner to complete the clinical program (phase III) and commercialize. 
  • Both products fulfill the U.S. FDA Priority Review Voucher (PRV) criteria. 
  • This project is supported by a $3.7 million grant from the Singaporean government (MOH). 

The 60P Malaria Program

Malaria causes 548,000 fatalities and 200 million clinical cases annually. Though therapies exist, such as treatment drugs and a partially effective vaccine, the goal of elimination is not achievable with current tools. A potentially fatal disease in malaria-naïve travelers, workers, NGO employees, and military forces deployed to malaria-endemic countries.

While several marketed antimalarials are available, none can be administered weekly, are effective everywhere in the world, or have utility against both the disease-causing and latent forms of the parasite.
  • 60P secured research and licensing agreements with the U.S. Army, including sponsorships rights, exclusive access to a clinical dossier, and use patents for malaria prophylaxis. 
  • The legacy clinical program includes a completed phase III study. 
  • Due to its long half-life, activity against all stages of the malaria parasite, and lack of drug resistance, tafenoquine is an ideal drug candidate for community prophylaxis in endemic countries and for malaria prevention in travelers. 
  • Current plans are for regulatory filings in late 2017 and subsequent commercial launch in selective markets in 2018. 
  • Development program support by $18 million-plus in-kind financing provided by U.S. Army.

About  |  Tropical Diseases  |  Products  |  Research  |  Responsibility  |  Investors  |  Media  |  Careers  |  Contact 

 1025 Connecticut Avenue NW, Suite 1000   Washington DC 20036 
Phone: 1-240-351-1167   Email: 

 Content © 2017. 60° Pharmaceuticals, LLC. All rights reserved.